
Triple-receptor metabolic firepower.
Retatrutide 50mg/3mL — triple agonist of GLP-1, GIP, and Glucagon receptors.
Reta Max delivers Retatrutide, a next-generation triple agonist engineered for maximum metabolic recomposition.
Simultaneous activation of GLP-1, GIP, and Glucagon receptors compounds satiety, insulin sensitivity, and basal metabolic output for unparalleled recomposition.
Week 1–2: 15 clicks (2.5 mg) weekly. Week 3+: titrate to 30 clicks (5 mg). Maintenance: 10 mg as needed.
Weekly subcutaneous injection via the pen. Rotate between abdomen, thigh, and upper arm.
Refrigerate at 2–8 °C. Protect from light. Do not freeze.
Most users report measurable changes within 2–4 weeks of consistent use. Full results typically emerge across an 8–12 week protocol.
Yes. Our compounds are designed to be modular. Pair with complementary stacks from Recovery, Longevity, or Metabolic collections — our specialists can recommend a structure.
Every batch ships with a Certificate of Analysis verifying purity above 99% from an independent ISO-accredited lab.
Unopened, temperature-intact vials may be returned within 14 days. Opened compounds are non-returnable for safety reasons.
MetabolicSLU-PP-332 AMPK activator that mimics the metabolic signature of endurance training.
MetabolicTirzepatide 60mg/3mL — GLP-1 / GIP dual agonist for advanced fat loss.
MetabolicPre-filled 60mg/3ml MOTS-c pen — mitochondrially encoded peptide that boosts metabolic flexibility.
MetabolicTirzepatide — the GIP/GLP-1 dual agonist for appetite, glucose, and body composition.